Global Thulium-170 Market Strategic Research Report

Scope of the Report

The global Thulium-170 market size is predicted to grow from US$ 12.76 million in 2025 to US$ 22.46 million in 2032; it is expected to grow at a CAGR of 6.9% from 2026 to 2032.

In 2025, global Thulium-170 production was approximately 3,100,000 mCi, with a global average market price of around $4.00 per mCi. That year, total global production capacity for Thulium-170 reached approximately 4,600,000 mCi, and the industry's average gross profit margin stood at about 37%. Thulium-170 (Tm-170) is an artificial radioisotope of the element thulium, characterized by an atomic number of 69, a mass number of 170, and a half-life of approximately 128.6 days. It primarily decays via beta-minus (β⁻) emission into stable Ytterbium-170 (Yb-170), accompanied by low-energy gamma rays and characteristic X-rays. Due to its relatively low radiation energy and the ability to utilize compact shielding, it is well-suited as a radiation source for the non-destructive testing (NDT) of thin-walled materials and for experimental research.

The upstream segment primarily encompasses high-purity natural Thulium-169 raw materials, thulium oxide or metallic thulium targets, target cladding materials, and research reactors with associated neutron irradiation facilities. Since natural thulium consists almost entirely of the stable isotope Thulium-169, Tm-170 is typically produced via the ¹⁶⁹Tm(n, γ)¹⁷⁰Tm reaction, eliminating the need for complex pre-irradiation isotope enrichment. Key upstream barriers include the preparation of high-purity targets, reactor neutron flux capabilities, irradiation scheduling, radiological handling capabilities, and qualifications for nuclear material transport. The midstream segment involves target encapsulation, reactor irradiation, cooling, radiochemical analysis, activity calibration, sealed source fabrication, quality inspection, and compliant packaging and transport. Because the produced Tm-170 and unreacted Tm-169 are isotopes of the same element—making separation via standard chemical methods difficult—the product's specific activity is primarily determined by neutron flux, irradiation duration, and target characteristics. Producers must control radioactive impurities, source core dimensions, activity uniformity, and seal integrity, while offering products in forms such as oxides, solutions, foils, or sealed radioactive sources based on customer requirements. Downstream applications primarily include industrial NDT, research in nuclear physics and radiation technology, instrument calibration, and experimental medical research. In the industrial sector, its low-energy photons enable close-range radiography of thin-walled metal components, small-diameter piping, welds, and precision parts; in the scientific research sector, it is used for detector response testing, shielding material evaluation, dosimetry, and nuclear decay studies. Thulium-170 has also been investigated for use in brachytherapy, bone pain palliation, and as a radioisotope heat source; however, these applications generally remain in the research or specific project implementation stage and have not yet developed into a large-scale market comparable to that of nuclides such as Cobalt-60 and Iridium-192.

The development of Thulium-170 (Tm-170) has been primarily driven by the demand for industrial non-destructive testing. Its low-energy photon emissions make it suitable for inspecting thin-walled metals, small-diameter pipes, precision welds, and electromechanical components; furthermore, it can be fabricated into compact, portable radiation sources that require no external power supply. Sectors such as petrochemicals, aerospace, shipbuilding, pressure vessel manufacturing, and on-site engineering inspection—which require lightweight equipment capable of operating in complex spaces—provide a market niche for Tm-170. However, given that Iridium-192, Selenium-75, Ytterbium-169, and digital X-ray systems remain the primary alternatives, Tm-170 is best positioned for applications requiring shallow penetration depths and specialized operating conditions, rather than as a wholesale replacement for traditional radiation sources.

Research into nuclear medicine and radiotherapy represents a potential driver for growth. Tm-170 undergoes primarily beta-minus (β⁻) decay with a half-life of approximately 128.6 days and emits low-energy photons; research areas include brachytherapy, localized tumor irradiation, bone pain palliation, and radioactive microsphere therapy. Its advantages lie in the ability to produce it via direct neutron activation of natural Thulium-169 (ensuring a relatively clear supply of target material) and the fact that low-energy radiation facilitates the control of radiation doses to surrounding tissues. Nevertheless, medical applications remain largely in the stages of preclinical research, dosimetry validation, or small-scale trials; short-term demand stems mainly from research institutions, so it should not yet be viewed as a mature, large-scale medical market.

Supply-side development is driven by the availability of irradiation resources in research reactors and capabilities in radioactive source manufacturing. Tm-170 is typically produced via the ¹⁶⁹Tm(n, γ)¹⁷⁰Tm reaction route. Industry barriers center on high-flux reactor scheduling, target design, specific activity control, impurity detection, hermetic encapsulation, and cross-border transport qualifications. Due to Tm-170's relatively short half-life—resulting in a continuous decline in activity during storage and transport—the industry is increasingly adopting an on-demand production model characterized by "confirmed order → target irradiation → activity calibration → rapid delivery," alongside strategies such as regionalized supply, delivery cycle management, and pricing models that account for activity loss due to decay.

This report presents a comprehensive overview of the global Thulium-170 market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Thulium-170 Chloride
• Thulium-170 Oxide
• Thulium-170 Metal
• Chelate

Segment by Radioactivity

• Low Activity (<100 mCi)
• Medium Activity (100 mCi–20,000 mCi)
• High Activity (20,000–200,000 mCi)

Segment by Manufacturing Method

• Direct Activation
• Solution Dispensing
• Surface Deposition
• Double-layer Sealing
• Micro Encapsulation

Segment by Radionuclidic Purity

• 95%-99%
• ＞99%

Segment by Application

• Nuclear Medicine
• Industrial Tracer
• Scientific Research

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Thulium-170 market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Nuclear Medicine, Industrial Tracer, Scientific Research evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact